Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (Bedaquiline) with efavirenz in healthy volunteers: AIDS clinical trials group study A5267

Journal of Acquired Immune Deficiency Syndromes

Volumn 59, Issue 5, 2012, Pages 455-462

  Dooley, Kelly E ^a   Park, Jeong Gun ^b   Swindells, Susan ^c   Allen, Reena ^d   Haas, David W ^e   Cramer, Yoninah ^b   Aweeka, Francesca ^f   Wiggins, Ilene ^a   Gupta, Amita ^a   Lizak, Patricia ^f   Qasba, Sonia ^g   Van Heeswijk, Rolf ^h   Flexner, Charles ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d AIDS Clinical Trials Group Operations Center   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g TIBOTEC BVBA   (Belgium)

^h Montgomery County Department of Health and Human Services   (United States)

Author keywords

Bedaquiline; CYP3A; Efavirenz; HIV; Pharmacokinetics; TMC207; Tuberculosis

Indexed keywords

BEDAQUILINE; CYTOCHROME P450 2B6; EFAVIRENZ;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; MALE; MONOTHERAPY; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE;

ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; BENZOXAZINES; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; QUINOLINES; YOUNG ADULT;

EID: 84859753546     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182410503     Document Type: Article

References (36)

1. World Health Organization. Global tuberculosis control 2010. WHO/HTM/TB/2010.7. Available at: http://whqlibdoc.who.int/publications/2010/ 9789241564069-eng.pdf. Accessed October 26, 2011.
2. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362:697-706.
3. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretro-viral therapy with tuberculosis. N Engl J Med. 2011;365:1492-1501.
4. Blanc F, Sok T, Laureillard D, et al. Earlier versus later start of antire-troviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365:1471-1481.
5. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365: 1482-1491.
6. McIlleron H, Meintjes G, Burman WJ, et al. Complications of antiretro-viral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis. 2007;196 (suppl 1):S63-S75. (Pubitemid 47206086)
7. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science. 2005;307:223-227. (Pubitemid 40116230)
8. Lounis N, Veziris N, Chauffour A, et al. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother. 2006;50: 3543-3547. (Pubitemid 44684863)
9. Koul A, Dendouga N, Vergauwen K, et al. Diarylquinolines target sub-unit c of mycobacterial ATP synthase. Nat Chem Biol. 2007;3:323-324. (Pubitemid 46789271)
10. Ibrahim M, Andries K, Lounis N, et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother. 2007;51:1011-1015. (Pubitemid 46355288)
11. Veziris N, Ibrahim M, Lounis N, et al. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. PLoS One. 2011;6:e17556.
12. Shang S, Shanley CA, Caraway ML, et al. Activities of TMC207, rifam-pin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs. Antimicrob Agents Chemother. 2011;55:124-131.
13. Zhang T, Li SY, Williams KN, et al. Short-course chemotherapy with TMC-207 and rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med. 2011.
14. Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009; 360:2397-2405.
15. McNeeley D, Diacon AH, Pym A, et al. TMC-207 versus placebo plus OBT for the treatment of MDR-TB: a prospective clinical trial [abstract]. 41st Union World Conference on Lung Health; November 11-15, 2010; Berlin, Germany.
16. Matteelli A, Carvalho AC, Dooley KE, et al. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol. 2010;5:849-858.
17. Tibotec. Investigator's Brochure. TMC207-TIDP13. 6th ed. December 2010.
18. Haas DW, Gebretsadik T, Mayo G, et al. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans. J Infect Dis. 2009;199: 872-880.
19. Leger P, Dillingham R, Beauharnais CA, et al. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. J Infect Dis. 2009;200:955-964.
20. Division of AIDS. Table for grading the severity of adult and pediatric adverse events version 1.0. Available at: http://rsc.tech-res.com/Document/ safetyandpharmacovigilance/Table-for-Grading-Severity- of-Adult-Pediatric- Adverse-Events.pdf. Accessed October 26, 2011.
21. Hare CB, Mellors J, Krambrink A, et al. Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis. 2008; 47:421-424. (Pubitemid 352009367)
22. Sustiva [package insert]. Princeton, NJ: BMS; 2003.
23. Liu H, Ribaudo HJ, Acosta EP, et al. Pharmacogenetics of low plasma efavirenz (EFV) concentrations in AIDS Clinical Trials Group (ACTG) studies: Analysis NWCS 301. Presented at 12th International Workshop on Clinical Pharmacology of HIV Therapy; Miami, FL; April 2011.
24. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents\November 2009 [electronic version] Available at: http://www.who.int/hiv/pub/arv/rapid-advice-art.pdf. Accessed October 26, 2011.
25. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Rockville, MD: Department of Health and Human Services; January 10, 2011. Available at: http://www.aidsinfo.nih.gov/ContentFiles/Adultand AdolescentGL.pdf. Accessed October 26, 2011.
26. Andries K, Gevers T, Lounis N. Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. Antimicrob Agents Chemother. 2010;54:4540-4544.
27. Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52:2831-2835.
28. Reasor MJ, Hastings KL, Ulrich RG. Drug-induced phospholi-pidosis: issues and future directions. Expert Opin Drug Saf. 2006; 5:567-583. (Pubitemid 44468453)
29. Halliwell WH. Cationic amphiphilic drug-induced phospholipidosis. Toxicol Pathol. 1997;25:53-60 (Pubitemid 27100559)
30. United States Federal Drug Administration Advisory Committee. The regulatory challenges of drug-induced phospholipidosis. Presented at: ACPS meeting, April 14, 2010. United States Federal Drug Administration. Available at: http://www.fda.gov/downloads/advisorycommittees/committees meetingmaterials/drugs/advisorycommitteeforpharmaceuticalscienceand clinicalpharmacology/ucm210798.pdf. Accessed October 26, 2011.
31. Mesens N, Verbeeck J, Rouan MC, et al. Elucidating the role of M2 in the preclinical safety profile of TMC207. Abstract PS-71291-11. Presented at: 38th Union World Conference on Lung Health, November 8-12, 2007, Cape Town, South Africa.
32. Zhu M, Kaul S, Nandy P, et al. Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbama-zepine. Antimicrob Agents Chemother. 2009;53:2346-2353.
33. National Center for Biotechnology Information. dbSNP short genetic variations. Available at: http://www.ncbi.nlm.nih.gov/projects/SNP. Accessed October 26, 2011.
34. Mouly S, Lown KS, Kornhauser D, et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther. 2002;72:1-9. (Pubitemid 34833182)
35. Lounis N, Gevers T, Van Den Berg J, et al. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob Agents Chemother. 2008;52:3568-3572.
36. Faucette SR, Zhang TC, Moore R, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther. 2007;320:72-80. (Pubitemid 46025721)